Transplacental non-steroidal anti-inflammatory drugs versus expectant management in fetal Ebstein anomaly with circular shunt: Systematic review and meta-analysis.


Journal

Prenatal diagnosis
ISSN: 1097-0223
Titre abrégé: Prenat Diagn
Pays: England
ID NLM: 8106540

Informations de publication

Date de publication:
30 Oct 2023
Historique:
revised: 11 09 2023
received: 19 04 2023
accepted: 14 09 2023
medline: 30 10 2023
pubmed: 30 10 2023
entrez: 30 10 2023
Statut: aheadofprint

Résumé

Ebstein anomaly (EA) is a rare congenital cardiac malformation associated with high perinatal mortality. In this systematic review and meta-analysis, we aimed to investigate the outcomes of pregnancies affected by EA or tricuspid valve dysplasia (TVD) with circular shunt, focusing on two prenatal management approaches: (1) expectant management (EM) and (2) transplacental non-steroidal anti-inflammatory drugs (NSAID) therapy. We searched PubMed, Scopus, and Web of Science systematically from its inception until June 2023. The random-effect model was used to pool the data. Heterogeneity was assessed using the I

Identifiants

pubmed: 37902170
doi: 10.1002/pd.6446
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.

Références

Hoffman JI, Kaplan S, Liberthson RR. Prevalence of congenital heart disease. Am Heart J. 2004;147(3):425-439. https://doi.org/10.1016/j.ahj.2003.05.003
Freud LR, Escobar-Diaz MC, Kalish BT, et al. Outcomes and predictors of perinatal mortality in fetuses with Ebstein anomaly or tricuspid valve dysplasia in the current era: a multicenter study. Circulation. 2015;132(6):481-489. https://doi.org/10.1161/circulationaha.115.015839
Anderson KR, Zuberbuhler JR, Anderson RH, et al. Morphologic spectrum of Ebstein's anomaly of the heart: a review. Mayo Clin Proc. 1979;54(3):174-180.
Jost CHA, Connolly HM, Dearani JA, et al. Ebstein’s Anom. 2007;115(2):277-285.
Celermajer DS, Cullen S, Sullivan ID, Spiegelhalter DJ, Wyse RK, Deanfield JE. Outcome in neonates with Ebstein's anomaly. J Am Coll Cardiol. 1992;19(5):1041-1046. https://doi.org/10.1016/0735-1097(92)90291-t
Giuliani ER, Fuster V, Brandenburg RO, et al. Ebstein's anomaly: the clinical features and natural history of Ebstein's anomaly of the tricuspid valve. Mayo Clin Proc. 1979;54(3):163-173.
Andrews RE, Tibby SM, Sharland GK, Simpson JM. Prediction of outcome of tricuspid valve malformations diagnosed during fetal life. Am J Cardiol. 2008;101(7):1046-1050. https://doi.org/10.1016/j.amjcard.2007.11.049
Wertaschnigg D, Manlhiot C, Jaeggi M, et al. Contemporary outcomes and factors associated with mortality after a fetal or neonatal diagnosis of Ebstein anomaly and tricuspid valve disease. Can J Cardiol. 2016;32(12):1500-1506. https://doi.org/10.1016/j.cjca.2016.03.008
Sasikumar D, Sasidharan B, Sivasubramanian S. Demonstration of circular shunt in fetal Ebstein anomaly. Ann Pediatr Cardiol. 2015;8(3):249-250. https://doi.org/10.4103/0974-2069.154155
Torigoe T, Mawad W, Seed M, et al. Treatment of fetal circular shunt with non-steroidal anti-inflammatory drugs. Ultrasound Obstet Gynecol. 2019;53(6):841-846. https://doi.org/10.1002/uog.20169
Zimmer EZ, Blazer S, Lorber A, Solt I, Egenburg S, Bronshtein M. Fetal Ebstein's anomaly: early and late appearance. Prenat Diagn. 2012;32(3):228-233. https://doi.org/10.1002/pd.2935
Selamet Tierney ES, McElhinney DB, Freud LR, et al. Assessment of progressive pathophysiology after early prenatal diagnosis of the Ebstein anomaly or tricuspid valve dysplasia. Am J Cardiol. 2017;119(1):106-111. https://doi.org/10.1016/j.amjcard.2016.09.022
Freud LR, McElhinney DB, Kalish BT, et al. Risk factors for mortality and circulatory outcome among neonates prenatally diagnosed with ebstein anomaly or tricuspid valve dysplasia: a multicenter study. J Am Heart Assoc. 2020;9(21):e016684. https://doi.org/10.1161/jaha.120.016684
Yu JJ, Yun TJ, Won HS, et al. Outcome of neonates with Ebstein's anomaly in the current era. Pediatr Cardiol. 2013;34(7):1590-1596. https://doi.org/10.1007/s00246-013-0680-x
Pavlova M, Fouron JC, Drblik SP, et al. Factors affecting the prognosis of Ebstein's anomaly during fetal life. Am Heart J. 1998;135(6 Pt 1):1081-1085. https://doi.org/10.1016/s0002-8703(98)70076-6
Cieplucha A, Trojnarska O, Bartczak-Rutkowska A, et al. Severity scores for Ebstein anomaly: credibility and usefulness of echocardiographic vs magnetic resonance assessments of the celermajer index. Can J Cardiol. 2019;35(12):1834-1841. https://doi.org/10.1016/j.cjca.2019.08.003
Celermajer DS, Bull C, Till JA, et al. Ebstein's anomaly: presentation and outcome from fetus to adult. J Am Coll Cardiol. 1994;23(1):170-176. https://doi.org/10.1016/0735-1097(94)90516-9
Freud LR, Wilkins-Haug LE, Beroukhim RS, et al. Effect of in utero non-steroidal anti-inflammatory drug therapy for severe Ebstein anomaly or tricuspid valve dysplasia (NSAID therapy for fetal Ebstein anomaly). Am J Cardiol. 2021;141:106-112. https://doi.org/10.1016/j.amjcard.2020.11.013
Gill K, Arbic N, Seed M, Honjo O, Ryan G, Jaeggi E. Inadvertent irreversible closure of arterial duct following therapeutic use of transplacental indomethacin in a fetus with severe Ebstein's anomaly and circular shunt. Ultrasound Obstet Gynecol. 2021;58(6):940-942. https://doi.org/10.1002/uog.24758
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. https://doi.org/10.1016/j.ijsu.2021.105906
Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14(1):579. https://doi.org/10.1186/s12913-014-0579-0
Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc. 2018;106(4):420-431. https://doi.org/10.5195/jmla.2018.345
Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses; 2000.
Aromataris E, Munn Z, eds. JBI Manual for Evidence Synthesis. JBI; 2020. https://synthesismanual.jbi.global
R Core Team. A Language and Environment for Statistical Computing; 2013.
Team RJUhwrc. RStudio: Integrated Development Environment for R. RStudio, PBC; 2020.2020.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. https://doi.org/10.1186/1471-2288-14-135
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evidence-Based Ment Health. 2019;22(4):153-160. https://doi.org/10.1136/ebmental-2019-300117
Harrer M, Cuijpers P, Furukawa T, et al. Doing Meta-Analysis with R: A Hands-On Guide. Chapman and Hall/CRC; 2021.
Lopes LM, Bezerra RF, da Silva JP, da Fonseca da Silva L. Critical Ebstein's anomaly with circular shunt: from successful fetal therapy with non-steroidal anti-inflammatory drugs to biventricular repair using Da Silva cone technique. Cardiol Young. 2021;31(6):1039-1042. https://doi.org/10.1017/s1047951121000081
Wald RM, Adatia I, Van Arsdell GS, Hornberger LK. Relation of limiting ductal patency to survival in neonatal Ebstein's anomaly. Am J Cardiol. 2005;96(6):851-856. https://doi.org/10.1016/j.amjcard.2005.05.035
Barre E, Durand I, Hazelzet T, David N. Ebstein's anomaly and tricuspid valve dysplasia: prognosis after diagnosis in utero. Pediatr Cardiol. 2012;33(8):1391-1396. https://doi.org/10.1007/s00246-012-0355-z
Gottschalk I, Gottschalk L, Stressig R, et al. Ebstein's anomaly of the tricuspid valve in the fetus - a multicenter experience. Ultraschall Med. 2017;38(4):427-436. https://doi.org/10.1055/s-0042-107151
Hakim K, Boussaada R, Ayari J, et al. [Circular shunt in the severe neonatal form of Ebstein's Anomaly. The prostaglandine infusion is it beneficial or harmful?]. Cardiol Tunis. 2013;9(4):73-76.
Inamura N. Dynamic slow-motion display in the diagnosis of functional pulmonary atresia in fetal Ebstein anomaly. CASE. 2020;4(2):57-58. https://doi.org/10.1016/j.case.2019.07.009
Lasa JJ, Tian ZY, Guo R, Rychik J. Perinatal course of Ebstein's anomaly and tricuspid valve dysplasia in the fetus. Prenat Diagn. 2012;32(3):245-251. https://doi.org/10.1002/pd.2939
Masoller N, Gómez Del Rincón O, Herraiz I, et al. Prediction of perinatal mortality in Ebstein's anomaly diagnosed in the second trimester of pregnancy. Fetal Diagn Ther. 2020;47(8):604-614. https://doi.org/10.1159/000504979
Rato J, Sousa AR, Teixeira A, Anjos R. Ebstein's anomaly with 'reversible' functional pulmonary atresia. BMJ case Rep. 2019;12(12):e229809. https://doi.org/10.1136/bcr-2019-229809
Satomi G, Momoi N, Kikuchi N, Nakazawa M, Momma K. Prenatal diagnosis and outcome of Ebstein's anomaly and tricuspid valve dysplasia in relation to lung hypoplasia. Echocardiography. 1994;11(3):215-220. https://doi.org/10.1111/j.1540-8175.1994.tb01070.x
Sharland GK, Chita SK, Allan LD. Tricuspid valve dysplasia or displacement in intrauterine life. J Am Coll Cardiol. 1991;17(4):944-949. https://doi.org/10.1016/0735-1097(91)90877-c
Suneja A, Nalini, Agarwal N, Gupta S, Dev G, Jain N. Fetal Ebstein anomaly--a rare cause of non-immune hydrops. Indian J Pediatr. 1996;63(6):812-815. https://doi.org/10.1007/bf02730935
Tongsong T, Chanprapaph P, Khunamornpong S, Sirichotiyakul S. Sonographic features of Ebstein anomaly associated with hydrops fetalis: a report of two cases. J Clin Ultrasound. 2005;33(3):149-153. https://doi.org/10.1002/jcu.20102
Torigoe F, Ishida H, Ishii Y, et al. Fetal echocardiographic prediction score for perinatal mortality in tricuspid valve dysplasia and Ebstein's anomaly. Ultrasound Obstet Gynecol. 2020;55(2):226-232. https://doi.org/10.1002/uog.20302
Tsukimori K, Morihana E, Fusazaki N, Takahata Y, Oda S, Kado H. Critical Ebstein anomaly in a fetus successfully managed by elective preterm delivery and surgical intervention without delay after birth. Pediatr Cardiol. 2012;33(2):343-346. https://doi.org/10.1007/s00246-011-0124-4
Stulak JM, Dearani JA, Danielson GK. Surgical management of Ebstein's anomaly. In: Seminars in thoracic and cardiovascular surgery Pediatric cardiac surgery annual; 2007:105-111.
Powel JE, Kraus E, Reddy C, Lannaman K. Treatment of severe fetal Ebstein's anomaly with prenatal nonsteroidal anti-inflammatory therapy. Fetal Diagn Ther. 2022;49(5-6):245-249. https://doi.org/10.1159/000525593
Hickok DE, Hollenbach KA, Reilley SF, Nyberg DA. The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol. 1989;160(6):1525-1530. discussion 1530-1521. https://doi.org/10.1016/0002-9378(89)90880-6
Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006;40(5):824-829. https://doi.org/10.1345/aph.1g428
Campbell S, Clohessy A, O'Brien C, Higgins S, Higgins M, McAuliffe F. Fetal anhydramnios following maternal non-steroidal anti-inflammatory drug use in pregnancy. Obstet Med. 2017;10(2):93-95. https://doi.org/10.1177/1753495x16686466
Topuz S, Has R, Ermiş H, et al. Acute severe reversible oligohydramnios induced by indomethacin in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Exp Obstet Gynecol. 2004;31(1):70-72.
Shen O, Rabinowitz R, Lavie O, et al. Good fetal outcome following prolonged indomethacin induced anhydramnios. Case report. J Perinat Med. 1995;23(3):233-236.
Arunamata A, Axelrod DM, Bianco K, Balasubramanian S, Quirin A, Tacy T. Chronic antepartum maternal hyperoxygenation in a case of severe fetal Ebstein's anomaly with circular shunt physiology. Ann Pediatr Cardiol. 2017;10(3):284-287. https://doi.org/10.4103/apc.apc_20_17
Schidlow DN, Donofrio MT. Prenatal maternal hyperoxygenation testing and implications for critical care delivery planning among fetuses with congenital heart disease: early experience. Am J Perinatol. 2018;35(1):16-23. https://doi.org/10.1055/s-0037-1603991

Auteurs

Hiba J Mustafa (HJ)

Division of Maternal-Fetal Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
The Fetal Center at Riley Children's and Indiana University Health, Indianapolis, Indiana, USA.

Faezeh Aghajani (F)

BCNatal Fetal Medicine Research Center, Hospital Clínic and Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.

Zinah A Bairmani (ZA)

Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Asma Khalil (A)

Fetal Medicine Unit, St George's Hospital, St George's University of London, London, UK.
Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.

Classifications MeSH